Compare Permian Resources Corporation Class A Common Stock (PR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Permian Resources Corporation Class A Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Permian Resources Corporation Class A Common Stock trades at $24.13 (market cap $20.32B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Permian Resources Corporation Class A Common Stock is far larger — about 2.7× Spyre Therapeutics Inc. Common Stock's market cap, and Permian Resources Corporation Class A Common Stock pays a 2.6% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Permian Resources Corporation Class A Common Stock for 5 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PR | SYRE | |
|---|---|---|
Market Cap | $20.32B | $7.52B |
Volume | 10,979,775 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $24.49 | $108.92 |
52-Week Low | $12.09 | $22.18 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $23.32B | $6.52B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Permian Resources (PR) trades at $24.26, up 3.68% on the day and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with $5.07B revenue, 21.52% net income margin, and attractive valuation metrics including a P/E of 15.65 and EV/EBITDA of 5.83. Recent earnings show mixed results with Q2 2026 beating expectations by 59% while Q1 2026 missed estimates.
The outlook remains positive with 90% analyst buy ratings and $27.00 consensus price target representing 11% upside. Key opportunities include disciplined acquisition strategy and raised 2026 guidance, while risks involve oil price volatility and execution of capital spending plans. The stock offers growth potential but requires monitoring of quarterly execution consistency.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Permian Resources Corporation Class A Common Stock
Permian Resources explores for and produces oil and natural gas in the Permian Basin. Its operations are concentrated in the Delaware Basin of West Texas and New Mexico.
Read more on PR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
